Citations (0)
Keep up to date with the latest research on this topic with citation updates for this article.
Lung Cancer: Targets and Therapy
Volume 14, 2023 - Issue
COMMENTARY
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
& 
Saihong Ignatius Ou1 University of California Irvine School of Medicine, Department of Medicine, Orange, CA, 92868, USA;2 Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence[email protected]
https://orcid.org/0000-0002-1764-4975
https://orcid.org/0000-0002-1764-4975